Table 1.
Baseline characteristics of 20 patients treated with rituximab (RTX) for a lupus nephritis (LN)
| Pt/Gender (Age) Ethnicity | SLE/LN duration (years) | SLE Extrarenal Manifestations | Complement/ AntiDNA at inclusion | Previous IS Therapy | RTX Indication |
|---|---|---|---|---|---|
| 1/F (24) W | 2/1 | S, H, Se, GS | ↓ / + | Cs CYP (5) MMF HCQ | Rf |
| 2/F (20) W | 7/3 | S, A, Se, H | ↓ / + | Cs CYP (4) AZA HCQ | Rf |
| 3/F (27) W | 2/2 | S, A, APL, H | N / + | Cs CYP (3) MMF HCQ MTX | Rf |
| 4/M (23) B | 6/2 | S, A, APL, N, Se | ↓ / + | Cs CYP (7) MMF AZA HCQ | Rf |
| 5/F (33) As | 1/1 | F, A, H, M | ↓ / + | Cs CYP (6) MMF | Rf |
| 6/F (20) W | 9/5 | S, A, H | ↓ / + | Cs CYP (3) MMF AZA MTX | Rl |
| 7/F (18) B | 2/1 | F, S, A, H | ↓ / + | Cs CYP (6) MMF | Rf |
| 8/F (27) B | 1/0 | S, A, Se, H | ↓ / + | Cs CYP (3) | Rf |
| 9/F (19) W | 8/6 | Ad, Hep, Ret, H | N / + | Cs CYP (12) MMF HCQ | Rl |
| 10/F (31) W | 4/4 | A, Se, PE, H | ↓ / + | Cs CYP AZA | Rl |
| 11/F (23) B | 8/5 | S, A, H | ↓ / na | Cs CYP (6) AZA HCQ | Rl |
| 12 /F (28) As | 0/0 | S, Se, TMA, Sp | ↓ / + | — | 1st |
| 13/F (24) B | 12/12 | A, Se, H | ↓ / + | Cs CYP (8) AZA HCQ | Rl |
| 14/F (37) B | 1/1 | F, S, N, PE, H | N / + | Cs HCQ | Rf |
| 15/F (35) W | 4/4 | F, S, A, CT, H | ↓ / + | Cs; CYP (9) MMF AZA | Rl |
| 16 /F (17) B | 2/2 | F, S, H, A, Se | ↓ / - | Cs MMF HCQ | Rf |
| 17/F ( 21) W | 1/1 | APL | N / + | — | 1st |
| 18/F (22) As | 5/4 | A, H, Ad, Sp | ↓ / + | Cs CYP (7) MMF | Rf |
| 19/F (32) W | 3/1 | S, A, H | ↓ / - | Cs CYP (4) MMF HCQ MTX | Rf |
| 20/F (31) As | 8/8 | S, A, N, En | ↓ / + | Cs MMF AZA | Rf |
Extra-renal manifestations in bold: active manifestation at the time of RTX initiation. Therapy in bold: taken in the 3 mos before RTX. Age is in years. Pt, patient; F, female; As, Asian; B, black ethnicity; W, white ethnicity. SLE, systemic lupus erythematosus. S, cutaneous manifestation; H, haematological manifestation; Se, serositis; GS, Gougerot Sjögen disease; A, arthritis; APL, antiphospholipid syndrome; N, neurological manifestations; F, fever; M, myositis; Ad, adenomegalia; Hep, hepatitis; Ret, retinitis; PE, pulmonar embolism; TMA, thrombotic microangiopathy; Sp, splenomegalia; CT, cerebral thrombophlebitis; En, endocarditis; Complement = C3 and C4 levels: ↓, low; N, normal; Anti-DNA: anti-dsDNA antibody level: +, positive (above laboratory positivity level); -, negative; IS, immunosuppressive; Cs, corticosteroids, CYP, cyclophosphamide; CYP (X), cumulated dose of CYP in grams; MMF, mycofenolate mofetil; HCQ, hydroxyhloroquine; AZA, azathioprine; MTX, methotrexate; Rf, refractory disease; Rl relapsing disease; 1st, first line treatment for LN.